Menu
Empower your in-house solid tumor profiling research capabilities with MSK-IMPACT® powered with SOPHiA DDM™, a decentralized version of the rigorously validated comprehensive genomic profiling (CGP) test developed and used in clinical routine by Memorial Sloan Kettering Cancer Center (MSK)1.
Detect partner-agnostic fusions from minimal input RNA with SOPHiA DDM™ RNAtarget Technology.
Facilitate rapid results and longitudinal insights with MSK-ACCESS® powered with SOPHiA DDM™.
Adapted from Mandelker D, Ceyhan-Birsoy O (2020)2.
A major limitation of tumor-only sequencing is its inability to distinguish germline versus somatic mutations2. A study showed that a tumor-only approach could not definitively identify germline changes, resulting in false positives comprising up to one third of alterations detected, including in potentially actionable genes3. Having an accurate picture of a tumor’s molecular make up is crucial for informed decision-making.
MSK-IMPACT® powered with SOPHiA DDM™ streamlines results with a matched-normal approach, allowing you to detect tumor-specific somatic variants with certainty and clearly distinguish from germline mutations associated with cancer-risk.
Exceptional analytical performance4
In an end-to-end comparison of 167 FFPE + matched white blood cell DNA samples, MSK-IMPACT® powered with SOPHiA DDM™ achieved high analytical concordance with the centralized version used at MSK.
OPA, overall percent agreement; PPA, positive percent agreement. Concordance based on analysis between decentralized MSK-IMPACT® powered with SOPHiA DDM™ and single-site MSK-IMPACT® using 167 FFPE and matched WBC gDNA samples. Limit of detection analysis based on analysis with MSK-IMPACT® powered with SOPHiA DDM™ using 216 reference samples. Analytical assessment of RUO products.
Enhance your somatic mutation interpretation capabilities with curated, evidence-based information offered by MSK’s Precision Oncology Knowledge Base, OncoKB™. Easily accessed via a gene-level link-out, OncoKB™ further enhances the interpretive power of SOPHiA DDM™ analysis through rich, data-driven insights.
AstraZeneca and MSK have joined forces with SOPHiA GENETICS to revolutionize cancer research and treatment. Together, we are creating a decentralized global network for precision oncology testing, including underserved regions where access remains scarce.
Generating an unparalleled and comprehensive dataset sourced from diverse populations holds the potential for invaluable insights that could shape the future of global healthcare.
| Content | 505 genes |
|---|---|
| Diseases Covered | Multi-cancer (any solid tumor) |
| Detected Variants | • SNVs/Indels in 505 genes • CNVs (gene amplifications and deletions) in 490 genes • Intronic coverage of 23 genes for novel fusion detection • TERT promoter • MET exon 14 skipping • Tumor mutational burden (TMB) • Microsatellite instability (MSI) |
| Sample Type | Paired samples of DNA from FFPE and white blood cell (WBC) gDNA |
| Starting Material | Recommended 50 ng FFPE DNA (min. 10 ng), 50 ng white blood cell gDNA |
| Multiplexing (samples per run) | Illumina NovaSeq™ 550: Illumina NovaSeq™ 1000: Illumina NovaSeq™ 6000: Illumina NovaSeq™ X: |
| Library Preparation Time | 1.5 days |
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
